** Telehealth firm Hims & Hers Health's shares rise 1.23% to $27.23 premarket
** Brokerage BTIG starts coverage with buy rating, PT $35
** Says co is "disrupting healthcare with tech and convenience"
** Unlike pure tele-health platforms that rely on remote visits, HIMS offers access to medications and treatment plans, so company is better insulated from the risk of more people returning to in-person visits - brokerage
** BTIG estimates that over 50% of HIMS' members have a personalized treatment plan
** Expects revenue growth and demand for GLP-1 and other obesity health products to remain robust
** We believe compounding for GLP-1s is here to stay - BTIG
** HIMS offers compounded versions of Novo Nordisk's
Wegovy and Ozempic
** Stock more than doubled last year
(Reporting by Sriparna Roy)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.